Pacira Pharmaceuticals (NASDAQ: PCRX) saw its stock plummet 7.99% in Friday's trading session following the release of its first-quarter 2025 financial results. Despite beating earnings estimates, the company's revenue fell short of analyst expectations, raising concerns about its growth trajectory.

The biopharmaceutical company reported Q1 revenue of $168.92 million, missing the analyst consensus estimate of $176.03 million by 4.03%. This represents a modest 1.08% increase from the same period last year. The revenue shortfall overshadowed Pacira's adjusted earnings per share of $0.62, which surpassed the analyst estimate of $0.60 by 3.33%.

While Pacira's adjusted EBITDA of $44.1 million exceeded the expected $41.2 million, and the company maintained its full-year 2025 financial guidance, investors appeared to focus on the top-line miss. The sharp stock decline suggests that market participants may be questioning Pacira's ability to meet its growth targets in an increasingly competitive pharmaceutical landscape. As the company navigates these challenges, all eyes will be on its ability to accelerate revenue growth in the coming quarters.